ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

On April 24, 2017, aTyr Pharma, Inc. (the Company) announced
further detail on the previously announced clinical data from the
Companys Phase 1b/2 Trial (004) in adult patients with limb
girdle muscular dystrophy type 2B (GLMD2B) and
facioscapulohumeral muscular dystrophy (FSHD) to be presented in
a poster presentation at the Emerging Platform Session at the
American Academy of Neurology 69th Annual Meeting on
Tuesday,April 25, 2017. The press release related to this
announcement is attached as Exhibit 99.1

The information under this Item 7.01, including Exhibit 99.1
hereto is being furnished and shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall such information be deemed
incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.

Item 8.01

Other Events

The poster referenced above is titled Results of a Phase 1b/2
Study of ATYR1940 in Adult Patients with Limb Girdle Muscular
Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular
Dystrophy (FSHD) (ATYR1940-C-004), and is filed as Exhibit 99.2
and incorporated herein by reference.

The poster presentation provides further detail on the previously
announced results from the completed Phase 1b/2 open-label,
intra-patient dose escalation 004 trial testing doses of
Resolaris (ATYR1940) of up to 3.0 mg/kg biweekly in patients with
LGMD2B and FSHD. Data from all clinical trials completed to date
demonstrate that Resolaris has a favorable safety profile and was
generally well-tolerated across all doses tested. There have been
no observed signs of general immunosuppression and low-level
anti-drug antibody signals did not result in clinical symptoms.
78% of the LGMD2B patients in the trial recorded increases in
muscle function at 14 weeks as measured by manual muscle test
(MMT) score, a validated assessment tool. 50% of the FSHD
patients in the trial recorded increases in muscle function as
measured by MMT score. The Company believes these data are
supportive of further advancement of Resolaris.

This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Litigation Reform
Act.Forward-looking statements are usually identified by the use
of words such as anticipates, believes, estimates, expects,
intends, may, plans, projects, seeks, should, will, and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including
statements regarding the potential and potential therapeutic
benefits of Resolaris, the ability of the Company to successfully
advance its pipeline or product candidates, undertake certain
development activities (such as clinical trial enrollment and the
conduct of clinical trials) and accomplish certain development
goals and the timing of such activities and development goals,
the timing of initiation of additional clinical trials and of
reporting results from our clinical trials, the scope and
strength of our intellectual property portfolio, our ability to
receive regulatory approvals for, and commercialize, our product
candidates and reflect our current views about our plans,
intentions, expectations, strategies and prospects, which are
based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected
in or suggested by those forward-looking statements are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected
by a variety of risks and factors that are beyond our control
including, without limitation, risks associated with the
discovery, development and regulation of our Physiocrine-based
product candidates, as well as those set forth in our most recent
Annual Report on Form 10-K for the year ended December 31, 2016
and in our other SEC filings. Except as required by law, we
assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.

Item 9.01 Exhibits.

(d) Exhibits.


Press Release of aTyr Pharma, Inc. dated April 24, 2017.


Poster presentation titled Results of a Phase 1b/2 Study
of ATYR1940 in Adult Patients with Limb Girdle Muscular
Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral
Muscular Dystrophy (FSHD) (ATYR1940-C-004).


aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

ATYR PHARMA, INC. (NASDAQ:LIFE) Recent Trading Information

ATYR PHARMA, INC. (NASDAQ:LIFE) closed its last trading session 00.00 at 3.05 with 24,088 shares trading hands.

An ad to help with our costs